Compass Therapeutics Announced At ESMO Saturday Phase 2/3 COMPANION-002 Tovecimig Plus Paclitaxel Met Primary ORR, Key Secondary PFS Endpoints In Advanced Biliary Tract Cancer, Reducing Progression Or Death Risk By 56%, With 62.2% Disease Control Rate Vs. 36.8%
Share
Why It Matters
Compass showed their cancer medicine worked better than expected in testing. When doctors watch this company, they can see the treatment helped patients live longer without their disease getting worse.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.